Skip to main content
. 2021 Feb 20;10(4):874. doi: 10.3390/jcm10040874

Table 4.

Comparison of progression of symptoms and lung disease in patients with RA-ILD according to radiological pattern (UIP or NSIP).

Variable UIP NSIP p Value
Duration of follow-up, mean (SD) 46.8 (14.5) 47.5 (14.9) 0.808
Pulmonary function testing
Last FVC, mean (SD) 67.6 (22.0) 78.6 (25.4) 0.037
Last FEV1<, mean (SD) 72.1 (21.9) 78.2 (20.7) 0.225
Last DLCO, mean (SD) 66.9 (18.5) 70.1 (16.7) 0.235
HRCT
Course 0.002
Progression, n (%) 27 (38.0) 9 (22.0)
Stabilization, n (%) 44 (62.0) 26 (63.4)
Improvement, n (%) 0 (0.0) 6 (14.6)
Progression of lung disease (total) * 0.032
Improvement, n (%) 2 (2.8) 6 (14.6)
Stabilization, n (%) 38 (53.5) 25 (61.0)
Worsening, n (%) 16 (22.5) 7 (17.1)
Death, n (%) 15 (21.1) 3 (7.3)
Inflammatory activity
Last DAS28, mean (SD) 3.3 (1.1) 3.2 (1.4) 0.428
Last C-reactive protein, mean (SD) 18.5 (16.9) 8.6 (7.3) 0.037
Last ESR, mean (SD) 26.1 (17.4) 23.2 (18.2) 0.823
Last HAQ, mean (SD) 1.5 (0.7) 1.2 (0.7) 0.341

RA: rheumatoid arthritis; ILD: interstitial lung disease; DMARD: disease-modifying antirheumatic drug; SD: standard deviation; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; DLCO: diffusing capacity of the lung for carbon monoxide; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; HRCT: high-resolution computed tomography; DAS28: 28-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; * Progression of lung disease (total): taking into account HRCT and pulmonary function testing (FVC and DLCO).